Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:8933168rdf:typepubmed:Citationlld:pubmed
pubmed-article:8933168lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:8933168lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:8933168lifeskim:mentionsumls-concept:C0027950lld:lifeskim
pubmed-article:8933168lifeskim:mentionsumls-concept:C0026473lld:lifeskim
pubmed-article:8933168lifeskim:mentionsumls-concept:C0282636lld:lifeskim
pubmed-article:8933168lifeskim:mentionsumls-concept:C0002199lld:lifeskim
pubmed-article:8933168lifeskim:mentionsumls-concept:C0524910lld:lifeskim
pubmed-article:8933168lifeskim:mentionsumls-concept:C1280500lld:lifeskim
pubmed-article:8933168lifeskim:mentionsumls-concept:C0596873lld:lifeskim
pubmed-article:8933168lifeskim:mentionsumls-concept:C0017262lld:lifeskim
pubmed-article:8933168lifeskim:mentionsumls-concept:C0008897lld:lifeskim
pubmed-article:8933168lifeskim:mentionsumls-concept:C2911684lld:lifeskim
pubmed-article:8933168lifeskim:mentionsumls-concept:C0185117lld:lifeskim
pubmed-article:8933168pubmed:issue4lld:pubmed
pubmed-article:8933168pubmed:dateCreated1997-3-3lld:pubmed
pubmed-article:8933168pubmed:abstractTextPolymorphonuclear cell (PMN) oxidative metabolism, lymphocyte polyclonal proliferation and monocyte HLA class I antigen expression were evaluated at different intervals of time in patients with chronic hepatitis C (CH-C) subjected to a 6 month interferon alpha (IFN-alpha) treatment and divided into Responder ('R') and Nonresponder ('NR') subsets according to clinical outcome. Before therapy, all subjects exhibited multiple immune alterations even if to a different extent between 'R' and 'NR' subsets: an elevated superoxide anion (O2-) generation by suspended PMN, a failure to further increase neutrophil oxidative responsiveness under adherence conditions, an augmented phytohaemagglutin-induced lymphocyte proliferative capacity and an enhanced HLA class I antigen expression on CD14+ cells. IFN-alpha administration gave rise to a modulation of oxidative response in 'R' group only, since these individuals displayed an O2- release by suspended and adherent PMN which fell within normal values. At the same time, a decrease of lymphocyte proliferation occurred in both groups of patients during IFN-alpha therapy, even if it reached statistical significance in 'R' group only. Finally, a more marked difference between 'R' and 'NR' individuals was noted in terms of HLA class I antigen induction on CD14+ cells at the end of therapy, as a consequence of a reduced expression of these structures in 'NR' subjects. Altogether, these findings suggest the occurrence of a strict relationship between immunoresponsiveness and IFN-alpha induced therapeutical effects in CH-C patients.lld:pubmed
pubmed-article:8933168pubmed:languageenglld:pubmed
pubmed-article:8933168pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8933168pubmed:citationSubsetIMlld:pubmed
pubmed-article:8933168pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8933168pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8933168pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8933168pubmed:statusMEDLINElld:pubmed
pubmed-article:8933168pubmed:monthNovlld:pubmed
pubmed-article:8933168pubmed:issn0892-3973lld:pubmed
pubmed-article:8933168pubmed:authorpubmed-author:JirilloEElld:pubmed
pubmed-article:8933168pubmed:authorpubmed-author:AntonaciSSlld:pubmed
pubmed-article:8933168pubmed:authorpubmed-author:SchiraldiOOlld:pubmed
pubmed-article:8933168pubmed:authorpubmed-author:AntonelliGGlld:pubmed
pubmed-article:8933168pubmed:authorpubmed-author:TortorellaCClld:pubmed
pubmed-article:8933168pubmed:authorpubmed-author:GiannelliGGlld:pubmed
pubmed-article:8933168pubmed:authorpubmed-author:PiazzollaGGlld:pubmed
pubmed-article:8933168pubmed:issnTypePrintlld:pubmed
pubmed-article:8933168pubmed:volume18lld:pubmed
pubmed-article:8933168pubmed:ownerNLMlld:pubmed
pubmed-article:8933168pubmed:authorsCompleteYlld:pubmed
pubmed-article:8933168pubmed:pagination529-48lld:pubmed
pubmed-article:8933168pubmed:dateRevised2009-5-14lld:pubmed
pubmed-article:8933168pubmed:meshHeadingpubmed-meshheading:8933168-...lld:pubmed
pubmed-article:8933168pubmed:meshHeadingpubmed-meshheading:8933168-...lld:pubmed
pubmed-article:8933168pubmed:meshHeadingpubmed-meshheading:8933168-...lld:pubmed
pubmed-article:8933168pubmed:meshHeadingpubmed-meshheading:8933168-...lld:pubmed
pubmed-article:8933168pubmed:meshHeadingpubmed-meshheading:8933168-...lld:pubmed
pubmed-article:8933168pubmed:meshHeadingpubmed-meshheading:8933168-...lld:pubmed
pubmed-article:8933168pubmed:meshHeadingpubmed-meshheading:8933168-...lld:pubmed
pubmed-article:8933168pubmed:meshHeadingpubmed-meshheading:8933168-...lld:pubmed
pubmed-article:8933168pubmed:meshHeadingpubmed-meshheading:8933168-...lld:pubmed
pubmed-article:8933168pubmed:meshHeadingpubmed-meshheading:8933168-...lld:pubmed
pubmed-article:8933168pubmed:meshHeadingpubmed-meshheading:8933168-...lld:pubmed
pubmed-article:8933168pubmed:meshHeadingpubmed-meshheading:8933168-...lld:pubmed
pubmed-article:8933168pubmed:meshHeadingpubmed-meshheading:8933168-...lld:pubmed
pubmed-article:8933168pubmed:meshHeadingpubmed-meshheading:8933168-...lld:pubmed
pubmed-article:8933168pubmed:meshHeadingpubmed-meshheading:8933168-...lld:pubmed
pubmed-article:8933168pubmed:year1996lld:pubmed
pubmed-article:8933168pubmed:articleTitleEffects of interferon-alpha treatment on neutrophil oxidative metabolism, lymphocyte proliferation and monocyte HLA class I antigen expression in patients with chronic hepatitis C.lld:pubmed
pubmed-article:8933168pubmed:affiliationDepartment of Internal Medicine, University of Bari Medical School, Italy.lld:pubmed
pubmed-article:8933168pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:8933168pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed